Skip to main content

Table 4 Impact of cannabinoid treatment, as reflected by change from baseline to end of treatment period 1 in total scores of HSQ-ASD, SRS-2, and APSI

From: Cannabinoid treatment for autism: a proof-of-concept randomized trial

  Median (range) [n] Pairwise P
Assessment Whole-plant extract Pure cannabinoids Placebo Whole-plant versus placebo Pure C. versus placebo Whole-plant versus pure C
HSQ-ASD  − 1.1 (− 3.8 to 1.6) [40]  − 0.7 (− 4.4 to 3.8) [42]  − 0.5 (− 3.7 to 2.5) [39] 0.575 0.915 0.508
SRS-2  − 14.9 (− 45 to 15) [34]  − 8.2 (− 69 to 45) [28]  − 3.6 (− 63 to 35) [36] 0.009 0.801 0.202
APSI  − 5.4 (− 39 to 13) [38]  − 4.9 (− 19 to 22) [42]  − 1.5 (− 26 to 20) [42] 0.502 0.513 0.991
  1. HSQ Home Situations Questionnaire–ASD; SRS-2 Social Responsiveness Scale-2nd edition; APSI Autism Parenting Stress Index
  2. Median tests were used, as distributions were non-normal
  3. P-values are based on Mood’s Median Test of each pairwise comparison